Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Publication year range
2.
An. pediatr. (2003, Ed. impr.) ; 70(4): 383-385, abr. 2009. ilus
Article in Spanish | IBECS | ID: ibc-59967

ABSTRACT

Se describe el caso de un varón de 10 meses, inmunocompetente, que presentó artritis séptica por Candida albicans en el período neonatal. Durante el ingreso recibió tratamiento con anfotericina B liposómica y al alta se le administró fluconazol. La evolución ha sido favorable y tras un año de seguimiento se encuentra asintomático. La aparición de artritis por C. albicans en un lactante inmunocompetente, con el antecedente de candidiasis sistémica en el período neonatal, es excepcional (AU)


We report the case of knee arthritis in an immunocompetent infant man, 10 month-old, caused by Candida albicans. He suffered in the past septic arthritis due to Candida albicans in the neonatal period. Initial management included treatment with liposomal amphotericin B and fluconazole at hospital discharge. Primary immunodeficiency was ruled out. Ongoing follow up during 1 year has been uneventful(AU)


Subject(s)
Humans , Male , Infant , Candida albicans/pathogenicity , Arthritis, Infectious/complications , Arthritis, Infectious/pathology , Immunocompetence/physiology , Amphotericin B/therapeutic use , Magnetic Resonance Imaging/methods , Ultrasonography/methods , Sepsis/pathology
3.
An Pediatr (Barc) ; 70(4): 383-5, 2009 Apr.
Article in Spanish | MEDLINE | ID: mdl-19268642

ABSTRACT

We report the case of knee arthritis in an immunocompetent infant man, 10 month-old, caused by Candida albicans. He suffered in the past septic arthritis due to Candida albicans in the neonatal period. Initial management included treatment with liposomal amphotericin B and fluconazole at hospital discharge. Primary immunodeficiency was ruled out. Ongoing follow up during 1 year has been uneventful.


Subject(s)
Arthritis, Infectious/microbiology , Candidiasis , Humans , Immunocompetence , Infant , Infant, Newborn , Male , Recurrence
6.
Acta pediatr. esp ; 66(8): 415-417, sept. 2008. ilus
Article in Es | IBECS | ID: ibc-69099

ABSTRACT

El impétigo es una infección cutánea superficial que ocurre sobre todo en la edad pediátrica, más frecuentemente por debajo de los 5 años de edad. SE clasifica en primario, que es el que tiene lugar sobre piel previamente sana, y secundario, que aparece en piel lesionada, principalmente tras un eccema. Existen dos tipos de impétigo: no bulloso, más frecuentemente, y bulloso. el agente causal predominante en todos los tipos de impétigo es Staphylococcus aureus. En los últimos años se ha descrito la emergencia de cepas de S. aureus resistentes a meticilina (SARM) como causantes de infecciones adquiridas en la comunidad, tanto leves como graves. Se presenta el caso de un varón de 8 años que presenta lesiones ampollosas dolorosas de una semana de evolución en la región lumbar. Se recoge cultivo de las lesiones y se identifica el crecimiento de colonias de S. aureus con resistencia a meticilina(AU)


Impetigo is a superficial skin disease that occurs in children, mainly before the age of five years. It is classified as primary if it occurs on previously healthy skin and secondary when it develops on damaged skin, usually following eczema. There are two types of impetigo: non-bullous, which is more frequent, and bullous. The predominant causative agent in both types is Staphylococcus aureus. In recent years, emergent methicillin-resistant strains (MRSA) that provoke mild to severe community-acquired lesions have been described. We report the case of an eight-year-old boy with painful, bullous skin lesions on his back that had developed one week earlier. A skin culture revealed the presence of colonies of methicillin-resistant S. aureaus(AU)


Subject(s)
Humans , Male , Child , Impetigo/diagnosis , Impetigo/drug therapy , Staphylococcus aureus/isolation & purification , Staphylococcus aureus/pathogenicity , Methicillin Resistance/physiology , Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use , Risk Factors , Methicillin Resistance , Methicillin Resistance/immunology , Leukocytosis/complications , Leukocytosis/diagnosis , Microbial Sensitivity Tests , Cross Infection/complications
SELECTION OF CITATIONS
SEARCH DETAIL
...